Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Mar 18, 2015 (12 years ago)

CARBOplatin Injection 450 mg/45 mL

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

CARBOplatin Injection 450 mg/45 mL (10 mg/mL), 45 mL packaged in a 100 mL Multi-Dose Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL 61103, Made in India, NDC 67457-493-46, UPC 3 67457 49346 6.

Affected NDC 67457-0493-46

Compare with the code on your package — it is the most precise check available.

Drug: Carboplatin

Recalling firm
Mylan Institutional LLC
NDC code
67457-493-46
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1331-2015 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Carboplatin recalls

See all
Class II · Moderate risk

Carboplatin active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-562-2015
Class II · Moderate risk

CARBOplatin Injection

Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.

Terminated Sterility / contamination Teva Pharmaceuticals USA, Inc. NDC 0703-3249-11 D-928-2013
Class I · High risk

Carboplatin Injection

Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.

Completed Failed specification Hospira Inc. NDC 61703-339-50 D-154-2013
Class I · High risk

Carboplatin Injection

Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.

Completed Failed specification Hospira Inc. NDC 61703-339-56 D-153-2013

Other recalls by Mylan Institutional LLC

All 2015 recalls